Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients

Summary

The purpose of this research is to assess the safety profile and clinical benefit of Awar-Awar leaf active fraction as a complementary therapy in chemotherapy of stage IV breast cancer

Eligibility

Inclusion Criteria:

* Female, at least 18 years old
* Welfare scale 0, 1, and 2 (ECOG - WHO)
* Patients with stage IV breast cancer who have histopathological data according to the TNM Classification of Malignant Tumors (TNM) from American Joint Committee on Cancer (AJCC) 8th edition 2017
* Patients who are willing to participate in the test and sign an informed consent
* Patients who undergo breast cancer chemotherapy with luminal B sub-type or triple negative with anthracycline base
* Patients who are willing and able to fill out a questionnaire
* The patients who are willing and able to comply with the test protocols during the test

Exclusion Criteria:

* Unable to meet the test protocol
* Patients with liver and kidney disorders
* Patients with other diseases/disorders that are meaningful according to the investigators will be excluded from the test
* Patients with cancer that has metastasized to the brain
* Pregnant women and breastfeeding mothers
* Patients with the ejection fraction smaller-than or equal to 55%

Conditions3

Browse More Trials